Avricore Health AI Stock Analysis
Avricore Health (AVCRF) AI Stock Analysis
Avricore Health
(Other OTC:AVCRF)
No summary available
Avricore Health (AVCRF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $81.03K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 1.00
- Revenue Growth
- -93.69%
- EPS Growth
- -26.73%
- Country
- US
- Employees
- 26
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Avricore Health Business Overview & Revenue Model
Company Description
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies...
Avricore Health Risk Analysis
Avricore Health disclosed 18 risk factors in its most recent earnings report. Avricore Health reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksAvricore Health Peers Comparison
Overall Rating
TSE:NARA47Neutral
TSE:BUX41Neutral
TSE:TELO40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | CAD 4.21M | -1.45 | 184.91% | ― | ― | 43.30% | |
| 41Neutral | CAD 44.72M | -31.11 | -250.77% | ― | -82.05% | 23.73% | |
| 40Underperform | CAD 4.51M | -1.96 | 295.03% | ― | ― | 25.57% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AVCRF | Avricore Health | 0.03 | -0.01 | -19.35% | |
| TSE:BUX | BioMark Diagnostics | 0.42 | 0.07 | 20.00% | |
| TSE:TELO | Telo Genomics | 0.04 | -0.03 | -35.71% | |
| TSE:SZLS.H | Stagezero Life Sciences | 0.04 | 0.00 | 0.00% | |
| TSE:NARA | PanGenomic Health, Inc. Class A | 0.30 | -0.60 | -66.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
